In Vitro Diagnostics Market : Global Industry Analysis and Opportunity Assessment, 2036

In Vitro Diagnostics Market Size, Market Forecast and Outlook By FMI

The in vitro diagnostics market was valued at USD 90.4 billion in 2025. The market is set to reach USD 94.7 billion by 2026-end and grow at a CAGR of 4.8% between 2026-2036 to reach USD 151.4 billion by 2036. Reagents will dominate with a 64.0% share, while Immunodiagnostics will lead with a 28.0% share.

Parameter	Details
Market Size in 2026 (Value)	USD 94.7 Bn
Market Forecast in 2036 (Value)	USD 151.4 Bn
CAGR (2026 to 2036)	4.8%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD Bn)
Leading Sub-Region	South Korea

Summary of the In Vitro Diagnostics Market

• Demand and Growth Drivers
  • Chronic disease prevalence and aging population demographics are generating sustained testing volumes across immunodiagnostics, hematology, and molecular diagnostics platforms in hospital and standalone laboratory settings.
  • Expansion of point-of-care and decentralized testing capabilities is creating new procurement channels for compact diagnostic platforms that deliver results at or near the patient without centralized laboratory processing.
  • Cancer screening program growth and companion diagnostics adoption are increasing molecular and tissue diagnostic testing volumes that command premium reagent pricing per test.
• Product and Segment View
  • Reagents are expected to account for 64.0% of the product segment in 2026, reflecting the consumable-driven revenue model where recurring reagent procurement generates the majority of diagnostic testing revenue.
  • Immunodiagnostics holds 28.0% of the technology segment, driven by the breadth of clinical applications spanning infectious disease, cardiac biomarker, thyroid, and tumor marker testing.
  • Blood samples account for 52.0% of the sample type segment, reflecting the concentration of routine chemistry, hematology, and immunoassay testing on serum and plasma specimens.
• Geography and Competitive Outlook
  • South Korea leads growth at 4.6% CAGR through 2036, driven by high healthcare system investment, MFDS regulatory pathways for diagnostic innovation, and smart manufacturing capabilities in diagnostic device production.
  • The USA at 4.5% reflects the scale of its laboratory testing market, CMS reimbursement for molecular and companion diagnostics, and the adoption of decentralized testing models.
  • Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers hold dominant positions through comprehensive platform portfolios, reagent menu breadth, and installed base advantages across hospital and reference laboratory networks.
• Analyst Opinion
  • Sabyasachi Ghosh, Principal Consultant at FMI says, 'Manufacturers that combine broad reagent menus with laboratory automation and data analytics capabilities are positioned to retain and grow share as testing volumes increase across centralized and decentralized diagnostic settings.'
  • The in vitro diagnostics market is evolving from standalone analyzer procurement toward integrated laboratory solutions where automation, informatics, and reagent supply are bundled into managed service contracts.
  • Adoption of molecular diagnostics for companion diagnostics, liquid biopsy, and infectious disease panel testing is increasing the average revenue per test across hospital and reference laboratory settings.
  • Demand is supported by the structural growth of testing volumes driven by aging populations, chronic disease management, and the expansion of screening programs across major healthcare systems.

In Vitro Diagnostics Market Definition

The in vitro diagnostics market includes medical devices, reagents, instruments, software, and services used to perform diagnostic tests on human specimens including blood, urine, tissue, and other body fluids outside the living body. Products span immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, and clinical chemistry platforms for disease detection, monitoring, and treatment guidance.

In Vitro Diagnostics Market Inclusions

Market scope encompasses all commercially traded IVD products categorized by product (reagents, instruments, services and software), technology (immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics), application (infectious diseases, cancer diagnostics, cardiac diseases, immune system disorders), end user (standalone laboratories, hospitals, academics and medical schools, point of care settings), deployment type (centralized diagnostics, decentralized diagnostics), and sample type (blood samples, urine samples, tissue samples, saliva and oral fluid samples). Revenue is tracked from 2026 to 2036.

In Vitro Diagnostics Market Exclusions

The scope does not include in vivo diagnostic imaging equipment, pharmaceutical drug testing kits, or veterinary diagnostic products.

In Vitro Diagnostics Market Research Methodology

• Primary Research: FMI analysts engaged with IVD manufacturers, hospital laboratory directors, reference laboratory procurement teams, and point-of-care testing coordinators across key healthcare markets.
• Desk Research: Combined testing volume data from healthcare systems, regulatory approval records, and reimbursement policy documentation for diagnostic procedures.
• Market Sizing and Forecasting: Bottom-up aggregation from testing volumes across technology platforms, application areas, and end-user settings with regional healthcare utilization curves.
• Data Validation: Cross-checked quarterly against manufacturer reagent shipment data, instrument placement records, and laboratory test volume statistics.

Why is the In Vitro Diagnostics Growing?

• Aging populations and the increasing incidence of chronic disease are boosting per capita diagnostic testing volumes, which is driving steady reagent consumption across immunoassay, chemistry and hematology platforms.
• The use of molecular diagnostics for companion diagnostics and infectious disease panel testing is also expanding the high-value testing segment that fuels premium per-test pricing.

Testing volumes in centralized and decentralized settings are increasing, which is driving the growth of the in vitro diagnostics market. The product segment is dominated by reagents at 64.0%. This is consistent with the business model, which is focused on consumables, with instrument placements generating long-term reagent revenue streams. Centralized diagnostics represent 62.0% of the deployment. Hospital core laboratories and reference laboratories perform most of the testing on high-throughput automated platforms.

The leader in technology is Immunodiagnostics with a 28.0% share. This technology is used in the greatest number of clinical applications, from infectious disease serology to cardiac biomarker and tumor marker testing. Molecular diagnostics is the fastest growing segment of technology, driven by PCR-based infectious disease panels, companion diagnostic testing for oncology treatment selection, and emerging liquid biopsy applications for cancer monitoring.

Infectious diseases represent 26.0% of the demand for applications, with routine and specialized testing targeting bacterial, viral and parasitic targets. The fastest growing application area is cancer diagnostics, driven by the need for companion diagnostics that connect specific test results with the choice of targeted therapy. Additional support for growth in diagnostic testing volumes includes expansion of screening programs for colorectal, cervical and lung cancers.

Market Segmentation Analysis

• In 2026, Reagent will represent 64.0% of the product segment, generating the majority of IVD revenue from recurring consumable purchases driven by installed instrument bases.
• Infectious diseases account for 26.0% of application demand, driven by routine and specialized testing in hospital, laboratory and point-of-care settings.
• Centralized diagnostics - 62.0% of deployment, testing volumes are centralized in hospital core laboratories and reference laboratories.

The in vitro diagnostics market has been segmented on the basis of product, technology, application, end user, deployment type and sample type. Product categories include reagents, instruments and services/software. Technology platforms include immunodiagnostics, hematology, molecular diagnostics and tissue diagnostics in centralized and decentralized deployment models.

Insights into the Reagents Segment

In 2026, reagents will dominate the product segment at 64.0%. Each time a test is performed, diagnostic reagents are used up, generating ongoing revenue streams that are independent of the capital equipment procurement cycles. Manufacturers leverage closed-system reagent architectures that tie reagent supply to specific instrument platforms to generate annuity revenue from the installed base.

Growth is driven by increasing volumes of tests per capita as healthcare systems expand screening programs, chronic disease monitoring and companion diagnostic testing. The range of reagents available is a competitive advantage, and manufacturers are dedicating resources to expanding assay development to increase the clinical utility of their platforms.

Insights into the Molecular Diagnostics Technology Segment

Molecular diagnostics is the fastest growing technology segment of IVD. PCR based infectious disease panels, next generation sequencing for oncology companion diagnostics and liquid biopsy assays for cancer monitoring are the main growth applications. Molecular assays have higher per-test cost than conventional immunoassay and chemistry testing, which supports higher revenue per test.

The demand is driven by the growing use of the technology for accurate identification of pathogens, the selection of therapies based on genetic biomarkers and non-invasive monitoring of cancer through analysis of circulating tumor DNA. Regulatory pathways such as FDA companion diagnostic approval and EU IVDR classification are shaping the commercial landscape for molecular diagnostic product.

In Vitro Diagnostics Market Drivers, Restraints, and Opportunities

• Aging populations and chronic disease prevalence are generating structural testing volume growth that sustains reagent consumption and instrument utilization across all diagnostic technology platforms.
• EU IVDR regulatory transition is increasing compliance costs and timelines for diagnostic product registration, creating market access barriers for smaller manufacturers.
• The development of Point-of-Care and decentralized testing is creating new market segments for small diagnostic platforms that provide rapid results away from typical laboratory settings.

In Vitro Diagnostics Market Dynamics Testing Volume Dynamics Regulatory Requirements Technology Evolution Growth is driven by demand for testing based on demographics, adoption of molecular diagnostics and proliferation of decentralized testing capabilities.

Demographic-Driven Testing Volume Growth

Aging populations in developed markets and rising chronic disease prevalence globally are increasing per-capita diagnostic testing volumes. Diabetes monitoring, cardiovascular risk assessment, cancer screening, and infectious disease surveillance all generate recurring testing demand that scales with population demographics and healthcare system access.

EU IVDR Regulatory Transition

The European Union In Vitro Diagnostic Regulation (IVDR) transition from the IVD Directive is increasing the regulatory burden for diagnostic product manufacturers. Higher classification requirements, clinical evidence expectations, and notified body capacity constraints are extending registration timelines and increasing compliance costs, creating barriers that favor large manufacturers with regulatory infrastructure.

Decentralized and Point-of-Care Testing Expansion

Tests are being deployed in decentralized settings such as emergency departments, outpatient clinics and community health centers where rapid results can enhance clinical decision making. Compact analyzers and cartridge-based testing platforms allow molecular and immunoassay testing to be performed outside of the traditional laboratory, opening up new procurement channels and revenue streams.

Analysis of In Vitro Diagnostics Market By Key Countries

Country	CAGR
USA	4.5%
UK	4.2%
EU	4.3%
Japan	4.4%
South Korea	4.6%

• South Korea leads the race with 4.6% CAGR over the forecast period. The growth is attributed to investments in the healthcare system, MFDS diagnostic innovation pathways and smart manufacturing for the production of diagnostic devices.
• The USA at 4.5% is indicative of the size of the laboratory testing market, CMS reimbursement for molecular diagnostics, and adoption of decentralized testing.
• The demand is driven by the aging population demographics, cancer screening programs, and the evolution of the regulatory framework in Japan (4.4%) and the EU (4.3%).

The global in vitro diagnostics market is projected to expand at a CAGR of 4.8% from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.

Demand Outlook for In Vitro Diagnostics Market in South Korea

South Korea leads at 4.6% through 2036. MFDS regulatory pathways support rapid diagnostic innovation and approval. Samsung and other technology conglomerates invest in diagnostic device development, leveraging semiconductor and display manufacturing precision for biosensor and microfluidics production.

• MFDS regulatory pathways facilitate accelerated approval of diagnostic innovations including molecular and point-of-care platforms.
• Government R&D investment in biomedicine and medical devices encourages the development of domestic IVD manufacturers.
• Smart manufacturing capabilities enable precision production of diagnostic sensors and microfluidic components.

Sales Analysis of In Vitro Diagnostics Market in the United States

The USA grows at 4.5% through to 2036. CMS reimbursement pathways for molecular diagnostics and companion diagnostic testing continue to enable high-volume growth in high-value testing.” FDA regulatory frameworks governing laboratory-developed tests and point-of-care platforms dictate market access for diagnostic manufacturers.

• Premium per-test revenue supported by CMS reimbursement for companion diagnostics and molecular testing in oncology applications.
• Regulatory frameworks for diagnostic devices and laboratory-developed tests offered by the FDA provide pathways to market access.
• Decentralized testing adoption in urgent care and outpatient settings creates new instrument and reagent procurement channels.

Future Outlook for In Vitro Diagnostics Market in the European Union

The EU grows at 4.3% to 2036. The EU IVDR transition is changing the regulatory landscape, with stricter classification requirements driving manufacturers to invest more in compliance. Volume growth in molecular and tissue diagnostic testing from the expansion of cancer screening programs in member state.

• EU IVDR regulatory transition increases compliance requirements and reshapes diagnostic product market access timelines.
• Cancer screening program expansion across member states generates structured molecular diagnostic testing volume.
• EU MDR and IVDR alignment creates integrated regulatory frameworks for diagnostic device and companion diagnostic products.

In-depth Analysis of In Vitro Diagnostics Market in Japan

Japan to grow 4.4% through 2036. Testing volume growth supported by PMDA regulatory pathways for approval of diagnostic devices and aging population demographics. long qualification cycles for diagnostic reagents help maintain specification barriers for diagnostic reagents and maintain rigorous quality standards; this benefits established IVD manufacturers.

• The demographics of the aging population drive the highest diagnostic testing volumes per capita among the major markets.
• Long reagent qualification cycles and PMDA regulatory pathways create quality barriers that favor established manufacturers.
• Hospital laboratory consolidation is driving procurement of integrated automation and high-throughput analyzer platforms.

Opportunity Analysis of In Vitro Diagnostics Market in the United Kingdom

The UK grows at 4.2% through 2036. NHS laboratory consolidation and the shift toward hub-and-spoke diagnostic networks create procurement scale for high-throughput analyzer platforms. Post-Brexit UKCA marking requirements create parallel regulatory pathways for diagnostic products sold in the UK market.

• NHS laboratory network consolidation creates larger procurement contracts for integrated diagnostic platform solutions.
• Post-Brexit UKCA marking requirements mean separate regulatory compliance pathways for diagnostic products marketed into the UK.
• The expansion of the NHS cancer screening programme is driving growth in the volume of molecular diagnostic testing across hospital and reference laboratories.

Competitive Landscape and Strategic Positioning

• Roche Diagnostics leads the world with its full platform offering of immunoassay, clinical chemistry, molecular and tissue diagnostics and the industry’s broadest reagent menu.
• Abbott Laboratories and Siemens Healthineers compete on integrated core laboratory platforms, automating chemistry, immunoassay and hematology on integrated automation tracks.
• Danaher Corporation has two platforms that participate, Beckman Coulter (core laboratory) and Cepheid (molecular point-of-care), that are both centralized and decentralized diagnostic settings.

Roche Diagnostics is the market leader with an extensive range of diagnostics including the cobas immunoassay and chemistry platforms, Ventana tissue diagnostics and cobas molecular diagnostics. The company has the broadest reagent menu and the largest global installed base, generating substantial recurring revenue from the sale of consumable reagents.

Abbott Laboratories competes with its Alinity integrated core laboratory platform and its leading position in point-of-care diagnostics with the i-STAT and BinaxNOW product lines. Siemens Healthineers provides the Atellica chemistry/immunoassay and CLINITEK urinalysis platforms for hospital and reference labs.

Danaher Corporation participates through Beckman Coulter core laboratory analyzers and Cepheid GeneXpert molecular point-of-care testing systems. The combination of centralized and decentralized diagnostic platforms positions Danaher across the full spectrum of laboratory testing environments.

Key Companies in the In Vitro Diagnostics Market

Key global companies leading the in vitro diagnostics market include:

• Roche Diagnostics (Switzerland), Abbott Laboratories (USA), and Siemens Healthineers (Germany) hold global leadership through comprehensive platform portfolios, reagent menu breadth, and installed base scale across hospital, reference, and point-of-care laboratory settings.
• Danaher Corporation (USA) serves both centralized and molecular point-of-care segments through Beckman Coulter and Cepheid platforms.
• bioMerieux (France), Sysmex Corporation (Japan), and QuidelOrtho  (USA) compete through focused specializations in microbiology, hematology, and transfusion diagnostics respectively.

Competitive Benchmarking: In Vitro Diagnostics Market

Company	Platform Breadth	Reagent Menu	Installed Base	Geographic Reach
Roche Diagnostics	High	Very Broad	Dominant	Global
Abbott Laboratories	High	Broad	Strong	Global
Siemens Healthineers	High	Broad	Strong	Global
Danaher Corporation	High	Broad	Strong	Global
bioMerieux	Medium	Focused	Strong	Global
Sysmex Corporation	Medium	Focused	Strong	Global
QuidelOrtho	Medium	Focused	Moderate	Global
Beckman Coulter	High	Broad	Strong	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in In Vitro Diagnostics Market

• Roche Diagnostics, Portfolio Expansion, cobas Molecular Diagnostics Menu (2025) - Roche Diagnostics continued expanding its cobas molecular diagnostics portfolio with additional infectious disease testing capabilities, enhancing laboratory efficiency and supporting growing demand for advanced molecular diagnostics.
• Abbott Laboratories, Laboratory Automation Expansion, Alinity Diagnostics Platform (2025) - Abbott continued advancing global adoption of its Alinity diagnostics platform, enabling greater laboratory automation and integrated testing workflows across hospital and reference laboratory settings.

Key Players in the In Vitro Diagnostics Market

Major Global Players

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Danaher Corporation
• bioMerieux

Emerging Players/Startups

• Sysmex Corporation
• QuidelOrtho Hologic Inc.
• Qiagen N.V.
• DiaSorin S.p.A.
• Luminex Corporation

Report Scope and Coverage

Parameter	Details
Market size by 2036	USD 151.4 Bn
Growth rate	4.8% CAGR (2026 to 2036)
Forecast period	2026 to 2036
Base year value (2025)	USD 90.4 Bn
Key Segment Covered	Product, Technology, Application, End User, Deployment Type, Sample Type
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	USA, South Korea, UK, Japan, EU, 30 plus countries
Key companies profiled	Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, bioMerieux, Sysmex Corporation, QuidelOrtho , Hologic Inc.
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

In Vitro Diagnostics Market Segmented by Product:

• Reagents
  • Clinical Diagnostic Reagents
    • Immunoassay Reagents
    • Biochemistry Reagents
  • Molecular Diagnostic Reagents
    • PCR Reagents
    • Genetic Testing Kits
• Instruments
  • Analytical Instruments
    • Automated Analyzers
    • Diagnostic Imaging Support Systems
  • Molecular Diagnostic Instruments
    • PCR Systems
    • Sequencing Platforms
• Services and Software
  • Laboratory Information Systems
    • Diagnostic Data Management
    • Workflow Automation Solutions
  • Diagnostic Support Services
    • Instrument Maintenance Services
    • Cloud Based Diagnostic Platforms

In Vitro Diagnostics Market Segmented by Technology:

• Immunodiagnostics
  • Enzyme Linked Immunoassays
    • Infectious Disease Detection
    • Hormone Testing
  • Rapid Immunoassays
    • Point of Care Testing
    • Pregnancy and Fertility Testing
• Hematology
  • Blood Cell Analysis
    • Complete Blood Count Testing
    • Anemia Detection
  • Coagulation Testing
    • Blood Clotting Analysis
    • Hemostasis Monitoring
• Molecular Diagnostics
  • PCR Based Diagnostics
    • Infectious Disease Testing
    • Genetic Mutation Detection
  • Next Generation Sequencing
    • Oncology Diagnostics
    • Personalized Medicine Applications
• Tissue Diagnostics
  • Histopathology Testing
    • Cancer Tissue Analysis
    • Biopsy Diagnostics
  • Immunohistochemistry
    • Tumor Marker Detection
    • Precision Oncology Applications
• Clinical Chemistry
  • Blood Chemistry Analysis
    • Glucose Monitoring
    • Liver Function Testing
  • Urine Chemistry Testing
    • Kidney Function Analysis
    • Electrolyte Testing
• Other Technologies
  • Microbiology Diagnostics
    • Bacterial Culture Testing
    • Antimicrobial Susceptibility Testing
  • Cytogenetics and Flow Cytometry
    • Chromosome Analysis
    • Cell Based Diagnostics

In Vitro Diagnostics Market Segmented by Application:

• Infectious Diseases
  • Viral Disease Diagnostics
    • COVID Nineteen Testing
    • Hepatitis Detection
  • Bacterial Infection Diagnostics
    • Tuberculosis Testing
    • Sepsis Detection
• Cancer Diagnostics
  • Oncology Screening
    • Breast Cancer Diagnostics
    • Lung Cancer Detection
  • Precision Oncology
    • Companion Diagnostics
    • Tumor Biomarker Testing
• Cardiac Diseases
  • Cardiac Biomarker Testing
    • Troponin Testing
    • Heart Failure Monitoring
  • Cardiovascular Risk Assessment
    • Cholesterol Testing
    • Inflammation Marker Analysis
• Immune System Disorders
  • Autoimmune Disease Diagnostics
    • Rheumatoid Arthritis Testing
    • Lupus Detection
  • Allergy Diagnostics
    • Food Allergy Testing
    • Respiratory Allergy Analysis
• Nephrological Diseases
  • Kidney Function Testing
    • Creatinine Analysis
    • Glomerular Filtration Testing
  • Renal Disease Monitoring
    • Dialysis Patient Testing
    • Urine Protein Analysis
• Gastrointestinal Diseases
  • Digestive Disease Diagnostics
    • Liver Disorder Testing
    • Inflammatory Bowel Disease Testing
  • Gastrointestinal Infection Testing
    • Helicobacter Pylori Detection
    • Stool Analysis Testing
• Other Applications
  • Endocrine Disorder Diagnostics
    • Thyroid Function Testing
    • Hormone Level Analysis
  • Neurological Disease Diagnostics
    • Alzheimer Biomarker Testing
    • Neurodegenerative Disease Monitoring

In Vitro Diagnostics Market Segmented by End User:

• Standalone Laboratories
  • Independent Diagnostic Laboratories
    • High Volume Testing Centers
    • Reference Laboratory Services
  • Specialty Testing Laboratories
    • Genetic Testing Facilities
    • Pathology Service Providers
• Hospitals
  • Hospital Diagnostic Laboratories
    • Emergency Diagnostic Testing
    • Inpatient Laboratory Services
  • Multi Specialty Hospitals
    • Advanced Molecular Diagnostics
    • Critical Care Testing
• Academics and Medical Schools
  • Research Laboratories
    • Clinical Research Testing
    • Biomarker Discovery Programs
  • Medical Training Institutes
    • Teaching Laboratory Facilities
    • Experimental Diagnostic Research
• Point of Care Settings
  • Clinic Based Testing
    • Rapid Diagnostic Testing
    • Bedside Monitoring Applications
  • Home Based Diagnostic Testing
    • Self Testing Kits
    • Remote Patient Monitoring
• Other End Users
  • Blood Banks
    • Transfusion Testing
    • Donor Screening Programs
  • Public Health Laboratories
    • Disease Surveillance Testing
    • Population Screening Programs

In Vitro Diagnostics Market Segmented by Deployment Type:

• Centralized Diagnostics
  • Large Laboratory Networks
    • Reference Testing Facilities
    • Automated High Throughput Systems
  • Hospital Based Central Labs
    • Integrated Diagnostic Platforms
    • Advanced Data Management
• Decentralized Diagnostics
  • Point of Care Systems
    • Portable Diagnostic Devices
    • Rapid Testing Platforms
  • Home Care Diagnostics
    • Consumer Self Testing
    • Remote Monitoring Applications

In Vitro Diagnostics Market Segmented by Sample Type:

• Blood Samples
  • Whole Blood Testing
    • Routine Diagnostic Analysis
    • Emergency Testing Applications
  • Serum and Plasma Testing
    • Immunodiagnostic Applications
    • Biochemical Testing
• Urine Samples
  • Routine Urinalysis
    • Kidney Function Monitoring
    • Infection Detection
  • Specialized Urine Diagnostics
    • Drug Screening Applications
    • Metabolic Disorder Testing
• Tissue Samples
  • Biopsy Samples
    • Cancer Diagnostics
    • Histopathology Analysis
  • Cytology Samples
    • Cellular Diagnostics
    • Precision Medicine Applications
• Saliva and Oral Fluid Samples
  • Non Invasive Diagnostics
    • Hormone Testing
    • Infectious Disease Detection
  • Rapid Point of Care Testing
    • Home Diagnostic Applications
    • Genetic Screening
• Other Sample Types
  • Stool Samples
    • Gastrointestinal Diagnostics
    • Microbiology Testing
  • Cerebrospinal Fluid Samples
    • Neurological Disease Testing
    • Infection Monitoring

In Vitro Diagnostics Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO Essential Diagnostics List and In Vitro Diagnostic Device Standards. WHO.
• 2. International Organization for Standardization. (2025). ISO 15189 Medical Laboratory Quality and Competence Standards. ISO.
• 3. Roche Diagnostics. (2025). Annual Report: Diagnostics Division Performance and Platform Technology Review. Roche.
• 4. USA Food and Drug Administration. (2025). FDA In Vitro Diagnostic Device Classification and Approval Requirements. FDA.
• 5. European Commission. (2025). EU In Vitro Diagnostic Regulation (IVDR): Implementation and Market Impact Assessment. EC.

This bibliography is provided for reader reference.

This Report Answers

• Estimating the size of the market and how much money it will make from 2026 to 2036.
• Dividing up by product, technology, application, end user, deployment type, and sample type.
• Insights about more than 30 markets in the region.
• Analysis of IVD technology platforms including immunodiagnostics, molecular diagnostics, and hematology.
• Assessment of the competitive landscape.
• Finding investment opportunities in centralized laboratory, point-of-care, and molecular diagnostic applications.
• Keeping track of the supply chain.
• Delivery of data in PDF and Excel formats.